logo

ALUR

Allurion·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ALUR fundamentals

Allurion (ALUR) released its earnings on Nov 12, 2025: revenue was 2.66M (YoY -50.48%), beat estimates; EPS was -1.53 (YoY -992.86%), beat estimates.
Revenue / YoY
2.66M
-50.48%
EPS / YoY
-1.53
-992.86%
Report date
Nov 12, 2025
ALUR Earnings Call Summary for Q3,2025
  • FDA Approval Near: Final PMA review phase with no requested data; inspections passed without issues.
  • Restructured for Growth: Q3 2025 revenue $2.7M (-50% YoY) reflects strategic pivot; operating expenses down 29%.
  • Debt-Free Positioning: $5M private placement strengthens balance sheet ahead of U.S. launch.
  • Innovative Platform: Drug-eluting balloon and 12-month capsule in development to address adherence in chronic diseases.
EPS
Revenue

Revenue & Expenses

ALUR has released its 2025 Q3 earnings report, with revenue of 2.66M, reflecting a YoY change of -50.48%, and net profit of -11.88M, showing a YoY change of -236.03%. The Sankey diagram below clearly presents ALUR's revenue sources and cost distribution.

Key Indicators

Allurion (ALUR) key financial stats and ratios, covering profitability, financial health, and leverage.
Allurion (ALUR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Allurion (ALUR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Allurion (ALUR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Allurion (ALUR) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Allurion (ALUR) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield